Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Does Pfizer's Vaccine Authorization Improve Moderna's Chances?

By Keith Speights - Dec 18, 2020 at 8:15AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Here's what an immunotherapy scientist thinks.

Pfizer ( PFE -1.83% ) received U.S. Emergency Use Authorization (EUA) for its COVID-19 vaccine on Dec. 11, 2020. This has raised hopes that Moderna ( MRNA -4.54% ) could soon win EUA for its coronavirus vaccine as well. In this Motley Fool Live video recorded on Dec. 11, healthcare and cannabis bureau chief Corinne Cardina talked with immunotherapy scientist Dr. Leo Nissola about the potential for Pfizer's vaccine authorization to improve Moderna's chances of receiving an EUA for its vaccine.

Corrine Cardina: Do you see this as a sign that the Moderna vaccine candidate will also get the green light?

Dr. Leo Nissola: Well, first, I think that Moderna's vaccine has everything on positive to actually occur. So I do agree that Pfizer's vaccine being approved will mean that perhaps the data coming in from Moderna will also be positive.

But I haven't looked at the raw clinical data from those patients so I can't speak on behalf of Moderna. They are also a different company. They have a different history and we can't speak about Moderna with that amount of confidence right now.

Corrine Cardina: Absolutely. The FDA Advisory Committee will be convening next Thursday to look at that. So we will keep everyone posted with anything that comes out of that.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$296.51 (-4.54%) $-14.10
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$53.68 (-1.83%) $-1.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
635%
 
S&P 500 Returns
141%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/02/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.